CDKN2B and coronary atherosclerosis: In addition, cyclin-dependent kinase inhibitor 2B antisense RNA1 (ANRIL) may prevent coronary atherosclerosis [27], and increased plasma levels of the lncRNAs H19 and LIPCAR are linked to increased risk of CAD [28].